ClinicalTrials.gg
CompletedNCT05852418Updated Oct 19, 2026

Registry Study of Assistive Devices, Medicines and Healthcare Measures in ALS, SMA and Other Neurological Diseases.

An observational study in Amyotrophic Lateral Sclerosis, sponsored by Ambulanzpartner Soziotechnologie APST GmbH. Completed at 16 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Ambulanzpartner Soziotechnologie APST GmbH · Observational

How we know

Updated Oct 19, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
25,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany — 17 open to participants now, 26 under way, 6 of them phase 3. Amyotrophic Lateral Sclerosis · Germany.

Planned enrollment
Largest of 13
25,000 · median 200
Started
2015
with 5 others
Observational
13 of 76
5 open now
Registered
57th of 76
by date
Lead sponsor
3 of 76
Ambulanzpartner Soziotechnologie APST GmbH

Among the 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany, this one has the largest planned enrollment of the 13 observational ones that give a count, is one of 6 that started in 2015, is one of 13 observational ones, and was the 57th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

17 of the 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany, or all of them as a file.
02

Study summary

This registry study aims to collect data on the provision of assistive devices, medicines, and other healthcare measures, such as ventilation therapy and nutrition support, in patients with Amyotrophic lateral sclerosis (ALS), Spinal muscular atrophy (SMA) and other neurological disorders. The data collected should describe the clinical practice, meaning real-world evidence and patient-reported outcomes.

Read the detailed description

This registry study aims to collect data on the provision of assistive devices, medicines, and other healthcare measures, such as ventilation therapy and nutrition support, in patients with ALS, SMA and other neurological disorders. The data collected should describe the clinical practice, meaning real-world evidence and patient-reported outcomes. The collected data include clinical characteristics, medical history, assessment scales, such as ALS functional rating scale-revised (ALSFRS-R), prognosis indicators, such as ALS progression rate, biomarker data, such as serum Neurofilament light chain (sNfL), genetic data, such as the mutation status of SOD1, FUS, c9orf72, TARDBP in ALS, SMN1 in SMA patients, innovative drugs such as Tofersen, Nusinersen, Risdiplam, as well as symptomatic drugs, patient-reported outcome data being captured using questionnaires and established clinical scales on medication expectation and treatment satisfaction.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • ALS Registry study
  • SMA Registry study
  • ALS medication and care registry study
  • SMA medication and care registry study
  • NfL
  • Neurofilament light chain
  • ALSFRS-R
  • ALS-App
  • ALS
  • APST Research
  • Biomarker
  • Tofersen
  • Nusinersen
  • Risdiplam
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The cohort includes patients with ALS, SMA and other chronic neurological conditions who received care with assistive devices, remedies, medications, or nursing interventions.

Eligibility criteria

Inclusion Criteria: Diagnosis of a chronic neurological disease -

Exclusion Criteria: Lack of cooperation and unwillingness to store and share medical data collected in the registry study

-

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
25,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The systematic recording of neurological treatment and its evaluation by patients via specific questionnaires

    The systematic recording of neurological treatment and its evaluation by patients via specific questionnaires

    Time frame: 10 years

07

Study locations

16 sites
  • Christoph Münch
    Berlin, State of Berlin 13353, Germany
  • Neurologische Klinik und Poliklinik, Universitätsklinikum Bergmannsheil
    Bochum, Germany
  • Klinik für Neurodegenrative Erkrankungen und Gerontopsychiatrie, ALS-Ambulanz und Huntington Ambulanz, Universitätsklinikum
    Bonn, Germany
  • Klinik und Poliklinik für Neurologie, Medizinische Fakultät Carl Gustav Carus, Technischen Universität Dresden
    Dresden, Germany
  • Neurologische Klinik, ALS-Ambulanz, Alfried Krupp Krankenhaus Rüttenscheid, Essen
    Essen, Germany
  • Klinik für Neurologie, Universitätsmedizin, Georg-August-Universität Göttingen
    Göttingen, Germany
  • ALS- und Muskelambulanz, Medizinische Hochschule Hannover
    Hanover, Germany
  • Neurologie und Poliklinik, Universitätsklinikum
    Heidelberg, Germany
  • Ambulanz für Neuromuskuläre und Motoneuron-Erkrankungen, Universitätsklinikum Jena
    Jena, Germany
  • Klinik und Poliklinik für Neurologie
    Leipzig, Germany
  • Klinik für Neuroogie-Präzisionsneurologie, Universitätsklinikum Schleswig-Holstein, Universität zu Lübeck
    Lübeck, Germany
  • Neurologisches Klinik, Ambulanz für Motoneuronerkrankungen und ALS, Diakonissenkrankenhaus
    Mannheim, Germany
  • Universitätklinikum
    Mannheim, Germany
  • Klinik und Poliklinik für Neurologie, Klinikum rechts der Isar der Technischen Universität München
    München, Germany
  • Klinik für Schlafmedizin und Neuromuskuläre Erkrankungen, Westfälische Willhelms-Universität Münster
    Münster, Germany
  • Klinik für Innere Medizin, Neurologie, UKM Marienhospital Steinfurt
    Steinfurt, Germany
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Dec 2024, 110 months.

Of 138 observational studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 114. This study's 110 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Dec 2028 → Dec 2024 and completion Jun 2029 → Dec 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2023
First posted
May 10, 2023
StartActual
Oct 30, 2015
Primary completionActual
Dec 2024was Dec 2028
CompletionActual
Dec 2024was Jun 2029
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 19, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 Germany)
  • Christoph Münch · Berlin, Germany
  • ALS- und Muskelambulanz, Medizinische Hochschule Hannover · Hanover, Germany
Show 2 removed
  • Christoph Münch · Berlin, Germany
  • ALS- und Muskelambulanz, Medizinische Hochschule Hannover · Hannover, Germany
Oct 19, 2026
Primary completion
Dec 31, 2028→Dec 2024 (actual)
Oct 19, 2026
Study completion
Jun 2029→Dec 2024 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Recruiting→Completed
    2 sites added, 2 sites removed
    Show 2 added (2 Germany)
    • Christoph Münch · Berlin, Germany
    • ALS- und Muskelambulanz, Medizinische Hochschule Hannover · Hanover, Germany
    Show 2 removed
    • Christoph Münch · Berlin, Germany
    • ALS- und Muskelambulanz, Medizinische Hochschule Hannover · Hannover, Germany
    Primary completion Dec 31, 2028→Dec 2024 (now actual)
    Study completion Jun 2029→Dec 2024 (now actual)
    + 4 other changes: verification date, criteria formatting, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05852418
Lead sponsor
Ambulanzpartner Soziotechnologie APST GmbH
Responsible party
Sponsor
First posted
May 10, 2023
Start date
Oct 30, 2015
Primary completion
Dec 2024
Completion
Dec 2024
Last update
Oct 19, 2026

Study contacts

Thomas Meyer, Prof. Dr.
study director · Ambulanzpartner Soziotechnologie APST GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion